Genomics

Life Science Industry in California Generates $376 Billion Annually

Retrieved on: 
Friday, December 2, 2022

Biocom California, the association representing the California life science industry, today released a new report showing Californias life science industry provides more than 400,000 jobs in the state and generates $376 billion in total economic output.

Key Points: 
  • Biocom California, the association representing the California life science industry, today released a new report showing Californias life science industry provides more than 400,000 jobs in the state and generates $376 billion in total economic output.
  • Biocom California's 2022 Economic Impact Report Databook outlines these and other key findings about the states life science industry, including information on economic, demographic, investment and industry performance data.
  • California continues to be the leading innovation hub for the life science industry and the 2022 Economic Impact Report provides key data on the impact it has on the state and regional economies, said Joe Panetta, president and CEO of Biocom California.
  • Over the last few years, and especially during the COVID-19 pandemic, the life science industry experienced an influx of investment interest and NIH funding for the sector.

The Mobile Health/Central Lab Interface, an opportunity for DCT efficiency

Retrieved on: 
Thursday, December 1, 2022

BRACKNELL, England, Dec. 1, 2022 /PRNewswire/ -- As the conversation around hybrid and decentralised clinical trials (DCT) moves from why to how, sponsors are increasingly seeking the best ways to embed the new model into their routine workflows.

Key Points: 
  • "Despite each of these service providers being dependent on the other to do their job, there is often no direct line of contact between the two.
  • Instead, the shared client becomes the key liaison for both, impairing effective communication, draining clinical trial efficiency, and placing additional burden on the sponsor."
  • The group will consider how the absence of communication between central laboratories and mobile health providers can contribute to inefficiencies, lead to duplicated efforts, and put data quality at risk.
  • Leveraging our next generation technologies, we deliver agile and precise services designed to meet the diverse needs of our clients.

The Mobile Health/Central Lab Interface, an opportunity for DCT efficiency

Retrieved on: 
Thursday, December 1, 2022

BRACKNELL, England, Dec. 1, 2022 /PRNewswire/ -- As the conversation around hybrid and decentralised clinical trials (DCT) moves from why to how, sponsors are increasingly seeking the best ways to embed the new model into their routine workflows.

Key Points: 
  • "Despite each of these service providers being dependent on the other to do their job, there is often no direct line of contact between the two.
  • Instead, the shared client becomes the key liaison for both, impairing effective communication, draining clinical trial efficiency, and placing additional burden on the sponsor."
  • The group will consider how the absence of communication between central laboratories and mobile health providers can contribute to inefficiencies, lead to duplicated efforts, and put data quality at risk.
  • Leveraging our next generation technologies, we deliver agile and precise services designed to meet the diverse needs of our clients.

Bio-Techne and Oxford Nanopore Technologies partner to bring innovative reproductive health and carrier screening solutions to the market

Retrieved on: 
Thursday, December 1, 2022

MINNEAPOLIS, Dec. 1, 2022 /PRNewswire/ -- Asuragen, a Bio-Techne brand (NASDAQ: TECH) and Oxford Nanopore Technologies plc (Oxford Nanopore) (LSE: ONT), today announce a collaboration to develop assays designed to deliver more accurate and reliable options for reproductive health and carrier screening. Asuragen will leverage its gold-standard PCR technology with Oxford Nanopore's any-read-length DNA sequencing capabilities to develop the first sequencing system to identify the most challenging yet high prevalence carrier genes in a single, unified workstream that today requires multiple other methods.

Key Points: 
  • MINNEAPOLIS, Dec. 1, 2022 /PRNewswire/ -- Asuragen,a Bio-Techne brand (NASDAQ: TECH) and Oxford Nanopore Technologies plc (Oxford Nanopore) (LSE: ONT), today announce a collaboration to develop assays designed to deliver more accurate and reliable options for reproductive health and carrier screening.
  • Carrier screening identifies at-risk-couples (ARCs) with pathogenic variants associated with severe genetic disorders.
  • This information can be used to determine the residual risk for passing on a condition to their children and help guide reproductive decision-making.
  • "We are really pleased to be working with Asuragen to develop more robust, reliable and accessible options for reproductive health and carrier screening," said Gordon Sanghera, Chief Executive Officer of Oxford Nanopore Technologies.

Partnership of BC Platforms, Euformatics, and Oncompass Medicine, Selected to Deliver Standardized Oncology NGS Workflows for Seven Major European Hospitals

Retrieved on: 
Thursday, December 1, 2022

This follows on from the announcement of 18 May 2022 about the three companies forming a partnership to deliver phase 1 of this 'Instand-NGS4P' project**.

Key Points: 
  • This follows on from the announcement of 18 May 2022 about the three companies forming a partnership to deliver phase 1 of this 'Instand-NGS4P' project**.
  • Instand-NGS4P is a Horizon 2020 funded project that shares BC Platforms vision for improving cancer patients' diagnostics.
  • BC Platforms, Euformatics, and Oncompass Medicine, have been working on designing the solution.
  • The consortium of BC Platforms, Euformatics and Oncompass Medicine was selected from several highly competitive applications, which were assessed in a multi-step peer-reviewed process.

Partnership of BC Platforms, Euformatics, and Oncompass Medicine, Selected to Deliver Standardized Oncology NGS Workflows for Seven Major European Hospitals

Retrieved on: 
Thursday, December 1, 2022

This follows on from the announcement of 18 May 2022 about the three companies forming a partnership to deliver phase 1 of this 'Instand-NGS4P' project**.

Key Points: 
  • This follows on from the announcement of 18 May 2022 about the three companies forming a partnership to deliver phase 1 of this 'Instand-NGS4P' project**.
  • Instand-NGS4P is a Horizon 2020 funded project that shares BC Platforms vision for improving cancer patients' diagnostics.
  • BC Platforms, Euformatics, and Oncompass Medicine, have been working on designing the solution.
  • The consortium of BC Platforms, Euformatics and Oncompass Medicine was selected from several highly competitive applications, which were assessed in a multi-step peer-reviewed process.

New CRISPR/Cas9 license agreement for ERS Genomics and Cosmo Bio

Retrieved on: 
Thursday, December 1, 2022

DUBLIN, Dec. 1, 2022 /PRNewswire/ -- ERS Genomics Limited ('ERS') is pleased to announce a new license agreement with Cosmo Bio.

Key Points: 
  • DUBLIN, Dec. 1, 2022 /PRNewswire/ -- ERS Genomics Limited ('ERS') is pleased to announce a new license agreement with Cosmo Bio.
  • This is a non-exclusive license agreement granting Japan's Cosmo Bio access to the ERS CRISPR/Cas9 patent portfolio.
  • We are pleased to support Cosmo Bio, a leader in high performance research biotools, in their ongoing development with this license agreement."
  • Media contact: Dara O'Donnell ERS Genomics Tel: + 353-1-539 0083
    Freedom to operate with CRISPR/Cas9 technology begins with a license to the foundational CVC patents available from ERS Genomics.

New CRISPR/Cas9 license agreement for ERS Genomics and Cosmo Bio

Retrieved on: 
Thursday, December 1, 2022

DUBLIN, Dec. 1, 2022 /PRNewswire/ -- ERS Genomics Limited ('ERS') is pleased to announce a new license agreement with Cosmo Bio.

Key Points: 
  • DUBLIN, Dec. 1, 2022 /PRNewswire/ -- ERS Genomics Limited ('ERS') is pleased to announce a new license agreement with Cosmo Bio.
  • This is a non-exclusive license agreement granting Japan's Cosmo Bio access to the ERS CRISPR/Cas9 patent portfolio.
  • We are pleased to support Cosmo Bio, a leader in high performance research biotools, in their ongoing development with this license agreement."
  • Media contact: Dara O'Donnell ERS Genomics Tel: + 353-1-539 0083
    Freedom to operate with CRISPR/Cas9 technology begins with a license to the foundational CVC patents available from ERS Genomics.

Si-Ware Partners with Eurofins Agro to Explore Applications for Feeds and Forages in Laboratory and Field Environments

Retrieved on: 
Wednesday, November 30, 2022

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20221130005283/en/
    Si-Ware and Eurofins Agro announce collaboration to explore laboratory and field applications for feeds and forages.
  • (Photo: Business Wire)
    Eurofins Agro is part of Eurofins Scientific, an internationally growing laboratory and contract research organization with over 61,000 personnel in 59 countries, operating in 940 laboratories.
  • With over 100 years of experience, Eurofins Agro has laboratories worldwide with a mission to contribute to healthy, viable, and sustainable farming and growing.
  • NeoSpectra is bringing a lot of opportunities to the table in terms of lab usage and portable field applications.

Personalis and UCSF to Study Clinical Utility of ctDNA for Treatment Response in Colorectal Cancer

Retrieved on: 
Wednesday, November 30, 2022

The research efforts will use Personalis NeXT Personal assay to evaluate circulating tumor DNA (ctDNA)-based signatures associated with treatment response and adverse events in a cohort of late-stage colorectal cancer patients receiving capecitabine together with pembrolizumab and bevacizumab.

Key Points: 
  • The research efforts will use Personalis NeXT Personal assay to evaluate circulating tumor DNA (ctDNA)-based signatures associated with treatment response and adverse events in a cohort of late-stage colorectal cancer patients receiving capecitabine together with pembrolizumab and bevacizumab.
  • Further, by leveraging the plasma sampling in this cohort, we aim to determine optimal sample collection timing for early identification of complete response and demonstrate clinical utility.
  • Personalis, Inc. is a leader in advanced cancer genomics, enabling the next generation of precision cancer therapies and diagnostics.
  • To enable cancer sequencing, Personalis' Clinical Laboratory was built with a focus on clinical accuracy, quality, big data, scale and efficiency.